small molecule compound

A unique collection of xnum annotated bioactive compounds with clear targets, suitable for phenotypic screening;

A unique collection of xnum approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of xnum anticancer drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A collection of xnum small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of xnum FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

The unparalleled chemical diversity of natural products makes them an ideal choice for screening active small molecules. Natural products is always a significant source in drug discovery. According to authoritative statistics, 79 out of 99 small molecule anticancer drugs have been successfully developed based on natural products since 1981. Natural products have demonstrated successful modulation of isolated but crucial targets, especially in antimicrobial targets and protein interactions. Many researchers consider natural products and their derivatives as unique tools for studying and manipulating protein function. The Drug-like Natural Compound Library comprises 522 novel molecules, serving as a complement to the L6000 Natural Product Library. This library enhances the probability of successful drug screening, making it an excellent tool for lead compound discovery.

xnum well-chosen unique AMPK-targeted small molecules;

A unique collection of xnum compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

A unique collection of xnum nuclear receptor signaling targeted compounds for high throughput and high content screening;

Membrane proteins are a class of proteins widely found in biological cell membranes, playing essential roles in the structure and function of cells. Based on their location and function, membrane proteins can be classified into three main categories: peripheral membrane proteins, integral membrane proteins, and lipid-anchored proteins. Membrane proteins encompass a variety of functional proteins, including glycoproteins, carrier proteins, and enzymes. They are often linked to carbohydrate molecules, which can transmit signals into the cell by undergoing structural changes, participating in signal transduction processes. Membrane proteins perform a range of critical functions, including substance transport, signal transduction, cell recognition, and energy conversion. In drug development, membrane proteins, especially G protein-coupled receptors (GPCRs), ion channels, and transporters, are of particular interest. Many diseases are related to the malfunction of specific membrane proteins. Therefore, drugs designed to target these proteins can regulate their activity, aiming to treat diseases. TargetMol has collected xnum compounds that target membrane proteins, which can be used for membrane protein-related scientific research and drug screening, suitable for high-throughput and high-content screening.

A unique collection of xnum approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum cancer cell differentiation inducing compounds for high throughput and high content screening;

xnum Chemotherapeutic drugs that can be used for high-throughput and high-content screening.

A unique collection of xnum compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening;

A unique collection of xnum compounds targeting ion channels for research in ion channels-related diseases and ion channel drug discovery;

A unique collection of xnum compounds targeting endocrine system for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of xnum glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer;

A unique collection of xnum bioactive compounds specifically targeting adrenergic receptors, effective tool for screening new drugs or new target identification;

xnum small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS) and a biological system's ability to readily detoxify the reactive intermediates or repair the resulting damage. Disturbances in the normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipids, and DNA. In humans, oxidative stress is thought to be involved in the development of atherosclerosis, heart failure, myocardial infarction, cancer, infection etc. Antioxidants are a class of compounds that counteract oxidative stress and reduce oxidative damage. The TargetMol Antioxidant Compound Library is a unique collection of xnum small molecules with inhibitory effects on oxidative stress and is a useful tool for high-throughput screening and high-content screening in the study of oxidative stress.